Beijing Biokiller Biotechnology

Beijing Biokiller Biotechnology is a Chinese biotechnology company specializing in the development of antimicrobial peptide (AMP) therapies and biological control solutions. As a subsidiary of the Wuhan Unioasis group, the company leverages a proprietary platform to create safe, environmentally friendly, and efficient biological products. Its lead clinical-stage product, Biokiller Oral Biological Antimicrobial Gel, is an AMP-based treatment for periodontitis that has reached Phase 4 clinical trials in China. The company's broader portfolio includes innovative biological pesticides and antimicrobial agents designed to improve human health and the living environment. Beijing Biokiller is headquartered in Beijing and maintains strong ties to academic research through its parent company's origins at Wuhan University.